Abstract
The development of colorectal carcinoma (CRC) has been hypothesized to be raised mostly from the precancerous lesion of colorectal adenoma (CRA) through a multistep process and defined as the adenoma-carcinoma sequence. In response to the tumorigenesis, host cellular immunity acts as the most important defense factor with cytokines as the main regulator molecules. Therefore, changes of cytokines of the T helper 1 (Th1)/T helper 2 (Th2) type immune responses along this sequence may therefore reflect a functional switch of host anti-tumor immunity. This minireview focused on the recent knowledge of the Th1/Th2 balance in the adenoma-carcinoma sequence and its potential clinical and therapeutical significance.
Keywords: Colorectal adenoma, colorectal carcinoma, tumor immunity, cytokine
Inflammation & Allergy - Drug Targets (Discontinued)
Title: Polarization of Cytokine Profile from Th1 into Th2 Along Colorectal Adenoma- Carcinoma Sequence: Implications for the Biotherapeutic Target?
Volume: 7 Issue: 2
Author(s): Guanglin Cui and Jon Florholmen
Affiliation:
Keywords: Colorectal adenoma, colorectal carcinoma, tumor immunity, cytokine
Abstract: The development of colorectal carcinoma (CRC) has been hypothesized to be raised mostly from the precancerous lesion of colorectal adenoma (CRA) through a multistep process and defined as the adenoma-carcinoma sequence. In response to the tumorigenesis, host cellular immunity acts as the most important defense factor with cytokines as the main regulator molecules. Therefore, changes of cytokines of the T helper 1 (Th1)/T helper 2 (Th2) type immune responses along this sequence may therefore reflect a functional switch of host anti-tumor immunity. This minireview focused on the recent knowledge of the Th1/Th2 balance in the adenoma-carcinoma sequence and its potential clinical and therapeutical significance.
Export Options
About this article
Cite this article as:
Cui Guanglin and Florholmen Jon, Polarization of Cytokine Profile from Th1 into Th2 Along Colorectal Adenoma- Carcinoma Sequence: Implications for the Biotherapeutic Target?, Inflammation & Allergy - Drug Targets (Discontinued) 2008; 7 (2) . https://dx.doi.org/10.2174/187152808785107589
DOI https://dx.doi.org/10.2174/187152808785107589 |
Print ISSN 1871-5281 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-4055 |
Related Articles
-
Editorial
Current Medical Imaging Editorial (Hot Topic: Development of New Molecular Agents Targeting Key Signalling Pathways Activated by Growth Factors in Human Cancer)
Current Pharmaceutical Design Hormone Replacement Therapy and Stroke
Current Vascular Pharmacology Radiolabeled Small Molecule Inhibitors of VEGFR - Recent Advances
Current Pharmaceutical Design <i>In Silico</i> Anticancer Evaluation, Molecular Docking and Pharmacophore Modeling of Flavonoids against Various Cancer Targets
Letters in Drug Design & Discovery Sugar Based Biopolymers in Nanomedicine; New Emerging Era for Cancer Imaging and Therapy
Current Topics in Medicinal Chemistry Targeting Histone Deacetylases in Neuroblastoma
Current Pharmaceutical Design Functionalized Upconversion Nanoparticles: Versatile Nanoplatforms for Translational Research
Current Molecular Medicine Intravitreal Anti-VEGF Drugs as Adjuvant Therapy in Diabetic Retinopathy Surgery
Current Diabetes Reviews Combination of Phytochemicals as Adjuvants for Cancer Therapy
Recent Patents on Anti-Cancer Drug Discovery Pharmacokinetics and In Vivo Fate of Drug Loaded Chitosan Nanoparticles<sup>++</sup>
Current Drug Metabolism Advances in Early Detection of Colorectal Cancer: A Focus on Non-invasive Biomarkers
Current Drug Targets Targeting Drugs Against Fibroblast Growth Factor(s)-Induced Cell Signaling
Current Drug Targets Distinguished Photons: A Review of In Vivo Spectral Fluorescence Imaging in Small Animals
Current Pharmaceutical Biotechnology EGFR-Targeting Monoclonal Antibodies in Head and Neck Cancer
Current Cancer Drug Targets Recent Patents and Advances in Genomic Biomarker Discovery for Colorectal Cancers
Recent Patents on DNA & Gene Sequences Studies on the IC<sub>50</sub> of Trisubstituted Thiazoles as Cdc7 Kinase Inhibitors
Letters in Drug Design & Discovery A Combined Approach with Rituximab Plus Anti-TRAIL-R Agonistic Antibodies for the Treatment of Haematological Malignancies
Current Pharmaceutical Design Biochemical Mechanisms of Cisplatin Cytotoxicity
Anti-Cancer Agents in Medicinal Chemistry CD95 Signaling in Cancer Treatment
Current Pharmaceutical Design